Ferric Carboxymaltose
drugOn this page
Also known as Carboximaltosa ferricaCarboxymaltose ferriqueInjectaferIron dextri-maltoseVIT-45
Summary
Ferric Carboxymaltose (CHEMBL2108597) is an approved unknown; indicated across 11 conditions including iron deficiency anemia and anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 11 conditions
- Clinical trials: 94
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108597 |
| Name | Ferric Carboxymaltose |
| Type | Unknown |
| Max phase | 4 |
Also known as: Carboximaltosa ferrica, Carboxymaltose ferrique, Ferric carboxymaltose, Injectafer, Iron dextri-maltose, VIT-45, FERRIC CARBOXYMALTOSE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| restless legs syndrome | 3 | MONDO:0005391 | EFO:0004270 |
| hip fracture | 3 | MONDO:0005327 | EFO:0003964 |
| inflammatory breast carcinoma | 3 | MONDO:0006804 | EFO:1000984 |
| female reproductive system neoplasm | 3 | MONDO:0021148 | MONDO:0021148 |
| gastric carcinoma | 3 | MONDO:0004950 | EFO:0000178 |
| chronic obstructive pulmonary disease | 2 | MONDO:0005002 | EFO:0000341 |
| myalgic encephalomeyelitis/chronic fatigue syndrome | 2 | MONDO:0005404 | EFO:0004540 |
| heart failure | 1 | MONDO:0005252 | EFO:0003144 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 94.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 38 |
| PHASE3 | 32 |
| Not specified | 14 |
| PHASE2 | 7 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04168346 | PHASE4 | NOT_YET_RECRUITING | Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer |
| NCT06686693 | PHASE4 | RECRUITING | Intravenous Iron Effects on Performance at High Altitude |
| NCT07053475 | PHASE4 | RECRUITING | IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches |
| NCT07370688 | PHASE4 | RECRUITING | Iron Infusion in Patients Undergoing Transcatheter Aortic Valve Implantation |
| NCT01100879 | PHASE4 | TERMINATED | Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy |
| NCT01245777 | PHASE4 | COMPLETED | Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy |
| NCT01701310 | PHASE4 | COMPLETED | IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia |
| NCT01913808 | PHASE4 | COMPLETED | Comparing Intravenous and Oral Iron in Postoperative Anemia |
| NCT01922479 | PHASE4 | COMPLETED | Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure |
| NCT01950247 | PHASE4 | COMPLETED | Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron |
| NCT01978028 | PHASE4 | TERMINATED | Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose |
| NCT02031289 | PHASE4 | COMPLETED | Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. |
| NCT02057471 | PHASE4 | COMPLETED | Intravenous Iron: Measuring Response in Anemic Surgical Patients |
| NCT02086968 | PHASE4 | COMPLETED | Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass |
| NCT02232906 | PHASE4 | COMPLETED | Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD) |
| NCT02544464 | PHASE4 | COMPLETED | Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery? |
| NCT02632760 | PHASE4 | COMPLETED | Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery |
| NCT02905539 | PHASE4 | COMPLETED | A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer |
| NCT02937454 | PHASE4 | COMPLETED | Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency |
| NCT03074591 | PHASE4 | COMPLETED | Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction |
| NCT03191201 | PHASE4 | TERMINATED | A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis. |
| NCT03295851 | PHASE4 | UNKNOWN | Preoperative Intravenous Iron Infusion to Reduce Post-surgical Complications: a Pilot Randomised Control Trial |
| NCT03380520 | PHASE4 | COMPLETED | Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy |
| NCT03466983 | PHASE4 | COMPLETED | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease |
| NCT03561480 | PHASE4 | UNKNOWN | Effect of Postoperative Ferric Carboxymaltose |
| NCT03561506 | PHASE4 | UNKNOWN | Effect of Preoperative Ferric Carboxymaltose After Simultaneous Bilateral Total Knee Arthroplasty |
| NCT03574311 | PHASE4 | UNKNOWN | Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery |
| NCT03632525 | PHASE4 | COMPLETED | Intravenous Iron in Adults With Cystic Fibrosis |
| NCT03680456 | PHASE4 | COMPLETED | Postoperative Replacement of Intraoperative Iron Losses |
| NCT03759964 | PHASE4 | COMPLETED | Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery |
| NCT03871699 | PHASE4 | UNKNOWN | Ferric Carboximaltose on Intra-myocardial Iron Load in Patients With Heart Failure |
| NCT04035902 | PHASE4 | UNKNOWN | Intraoperative IV Iron on Postoperative Red Blood Cell Recovery |
| NCT04627181 | PHASE4 | UNKNOWN | Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis? |
| NCT04786769 | PHASE4 | UNKNOWN | Iron Supplementation in TAVI and SAVR Patients With Iron Deficiency |
| NCT05358509 | PHASE4 | COMPLETED | Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial |
| NCT05477498 | PHASE4 | WITHDRAWN | Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction |
| NCT05702970 | PHASE4 | UNKNOWN | Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency |
| NCT06080893 | PHASE4 | COMPLETED | The Effect of Preoperative Ferric Carboxymaltose Administration on Mortality in Geriatric Hip Fractures |
| NCT05744219 | PHASE3 | RECRUITING | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial |
| NCT00396292 | PHASE3 | COMPLETED | Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).